EUVIMEDEUVIMED entdecken
Crossref

TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor

Chen Wang, Yaoyao Zhong, Senlin Xu, Wen Cai, Junwei Zhao, Jianmei Mao, Huaizhou Jin, Ching Ouyang, Yunfei Shi, Wing C Chan, Wendong Huang, Jiawei Zhang und 1 weitere

Drug Resistance Updates · 2025

DOI: 10.1016/j.drup.2025.101270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Chen Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) & Department of Colorectal Surgery and …. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Drug Resistance, Neoplasm, Glucocorticoids, RNA-Binding Protein FUS. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, University of Texas MD Anderson Cancer Center, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell lymphoma (TCL) is an aggressive malignancy with poor therapeutic outcomes, where glucocorticoid (GC) resistance remains a major challenge. Here, we identify TRIM24 as a critical regulator of GC receptor (GR) activity and a potential therapeutic target in TCL. TRIM24 deficiency delays TCL progression in murine models, suppresses cell proliferation, and enhances GC sensitivity by restoring GR transcriptional activity, as evidenced by transcriptomic and chromatin profiling. Mechanistically, TRIM24 interacts with Fused In Sarcoma (FUS) and promotes its liquid-liquid phase separation (LLPS) with GR, leading to impaired GR activity and heightened GC resistance. Moreover, TRIM24 is overexpressed in peripheral T-cell lymphoma (PTCL) samples, correlating with suppressed GR signaling and poor therapeutic response. These findings uncover an unrecognized "double-check" mechanism in which TRIM24 regulates nuclear GR function through FUS-facilitated LLPS. Importantly, targeting TRIM24 may provide a novel therapeutic strategy not only for overcoming GC resistance in TCL but also for addressing broader GR-dependent diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, GlucocorticoidDrug Resistance, NeoplasmGlucocorticoidsRNA-Binding Protein FUSLymphoma, T-CellCarrier ProteinsAnimalsMiceHumansCell ProliferationCell Line, TumorSignal TransductionMice, KnockoutGene Expression Regulation, NeoplasticPhase Separation

Stichwörter der Autor:innen

FUSGC resistanceGRLLPST-cell lymphomaTRIM24

Substanzen

Receptors, GlucocorticoidGlucocorticoidsRNA-Binding Protein FUSTRIM24 protein, humanCarrier Proteins

Autor:innen und Institutionen

  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) & Department of Colorectal Surgery and Oncology, Second Affiliated Hospital, School of Medicine, Zhejiang Uni…
  • Center for Genetic Medicine and Department of Urology, the Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang, China; Institute of Genetics, International School of Medicine, Zhejiang Un…
  • Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Key Laboratory of Quantum Precision Measurement, College of Science, Zhejiang University of Technology, Hangzhou, China.
  • Integrative Genomic Core, City of Hope National Medical Center, Duarte, CA, USA.
  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • University of Texas MD Anderson Cancer Center
  • National Natural Science Foundation of China

Zitieren

APA

Wang, C., Zhong, Y., Xu, S., Cai, W., Zhao, J., Mao, J., Jin, H., Ouyang, C., Shi, Y., Chan, W. C., Huang, W., Zhang, J., & Gu, Y. (2025). TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101270

Vancouver

Wang C, Zhong Y, Xu S, Cai W, Zhao J, Mao J, et al. TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101270

BibTeX
@article{Wang2025,
  author = {Wang, Chen and Zhong, Yaoyao and Xu, Senlin and Cai, Wen and Zhao, Junwei and Mao, Jianmei and Jin, Huaizhou and Ouyang, Ching and Shi, Yunfei and Chan, Wing C and Huang, Wendong and Zhang, Jiawei and Gu, Ying},
  title = {TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101270}
}
Kostenlos starten →